PROTACs, or proteolysis-targeting chimeras, comprise a novel class of therapeutic agents that aim to eradicate disease-causing proteins rather than merely inhibiting their activity. Each PROTAC molecule features a dual-binding structure, connected by a chemical linker, where one binding site attaches to the target protein and the other recruits an E3 ubiquitin ligase. This recruitment enables the target protein to be tagged with ubiquitin, subsequently broken down by the cell’s proteasome, a natural protein degradation mechanism. By facilitating this process, PROTACs offer a promising therapeutic approach for diseases with significant unmet medical needs.
Formulation Challenges Associated with PROTACs
Despite their therapeutic potential, PROTACs pose substantial formulation hurdles. Typically, these molecules exceed Lipinski’s Rule of 5, characterized by high molecular weight, hydrophobicity, and complex architecture, making them difficult to solubilize and formulate for oral administration. The poor aqueous solubility of PROTACs can impede dissolution in the gastrointestinal tract, increase the risk of precipitation, and result in variable or low bioavailability. For development teams working on PROTAC programs, these challenges are not merely technical in nature but can directly influence dose selection, exposure, safety, and the progression of the drug candidate towards clinical trials.
A primary concern in the formulation of PROTACs is their limited solubility, not only in water but also in biorelevant media and common excipients. This limitation complicates the creation of a stable and reproducible dosage form. If the solubilization of the drug is not maintained after administration, it may precipitate in the gastrointestinal tract, leading to reduced absorption and inconsistent exposure. For molecules with a narrow therapeutic index, such variability can raise the risk of suboptimal efficacy or adverse effects.
A second formulation challenge is the poor permeability of PROTACs. Due to their large and complex nature, these molecules may struggle to cross biological membranes. Even if a formulation enhances dissolution, the molecule must still permeate effectively to reach systemic circulation. Therefore, formulation development must consider the entire absorption process, encompassing solubility, dissolution, supersaturation, precipitation risk, permeability, and bioavailability.
The third significant challenge is ensuring safety control. When the therapeutic index is narrow, formulation decisions become critical. The objective is not only to increase exposure but to achieve predictable and controlled exposure. A formulation that is poorly designed can lead to precipitation, variable absorption, unexpected exposure, or dose-limiting toxicity. Consequently, the formulation of PROTACs requires a meticulous, molecule-specific approach from the outset of development.
Strategies for Effective Delivery of PROTACs
These formulation challenges can be overcome through a full and integrated approach to formulation development. The process commences with developability and pre-formulation studies, assessing factors such as solubility, permeability, stability, hygroscopicity, pKa, Log P, solid-form behavior, and excipient compatibility. These early assessments help identify potential risks and guide the selection of an appropriate formulation strategy.
For molecules that are poorly soluble and complex, various enabling formulation technologies can be employed, including amorphous solid dispersions, nanosuspensions, nanoemulsions, lipid-based systems, salt and co-crystal approaches, polymorph screening, micronization, and particle engineering. These technologies aim to enhance solubility, maintain the molecule in a form that can be absorbed, reduce the risk of precipitation, and support improved bioavailability and safety. Some technologies, such as lipid-based systems, can also enhance permeation.
Integrating Cross-Functional Teams for PROTAC Success
Teams must implement cross-functional decision-making to address these formulation challenges. Formulation experts need to collaborate closely with analytical development, particle science, DMPK, toxicology, medicinal chemistry, and process chemistry groups. This integrated model allows teams to design scalable, patient-appropriate dosage forms.
Effective PROTAC development requires a molecule-specific strategy from the earliest stages. An integrated approach helps transform complex degraders into reliable therapies. The formulation process is not a downstream activity but a key enabler of therapeutic success.
